It is reasonable to expect pharmaceutical and biotech companies to make greater strides in adapting to AI and robotics. By 2022 and beyond, the pharmaceutical and healthcare industries will be heavily invested in gene and cell therapy, monoclonal antibodies, and RNA-based therapeutics. Investors hold the shares of several pharmaceutical companies that consistently pay dividends as part of a diversified income portfolio. Bristol-Myers Squibb Company (BMY) is another well-known name in the pharmaceutical industry, as is AbbVie Inc. (ABBV).
Insider Monkey picked the best pharmaceutical stocks that recently received positive analyst ratings. An inhalation and intranasal product manufacturer and marketer, Amphastar Pharmaceuticals, Inc. is based out of California. Vasopressin, a blood pressure-raising drug, received provisional FDA approval on December 29. Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company specializing in the development of drugs for the treatment of pain. According to Needham analyst, the company’s acquisition of BioDelivery Sciences International, Inc. for $604 million is an “ideal” fit. Sales of $11,45 billion exceeded expectations by $53.68 million. Sanofi focuses on cardiovascular, central nervous system, type 2 diabetes, internal medicine, and oncology as therapeutic areas. Vaccines are developed by Dynavax Technologies Corporation. Hepatitis-B vaccine is the company’s best-known product. Newly approved COVID-19 injections and booster doses in India also contained its adjuvant. A biopharmaceutical company based in New York City, Regeneron Pharmaceuticals, Inc. A number of rare autoinflammatory conditions, including colorectal cancer, cardiovascular disease and rheumatoid arthritis, are treated by the company. For more details, click 10 Best Pharmaceutical Stocks To Buy In 2022.
Unsplash
